Cargando…

Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor

BACKGROUND: Increased endocannabinoid tonus by dual-action fatty acid amide hydrolase (FAAH) and substrate selective cyclooxygenase (COX-2) inhibitors is a promising approach for pain-relief. One such compound with this profile is 2-(2-fluorobiphenyl-4-yl)-N-(3-methylpyridin-2-yl)propanamide (Flu-AM...

Descripción completa

Detalles Bibliográficos
Autores principales: Gouveia-Figueira, Sandra, Karlsson, Jessica, Deplano, Alessandro, Hashemian, Sanaz, Svensson, Mona, Fredriksson Sundbom, Marcus, Congiu, Cenzo, Onnis, Valentina, Fowler, Christopher J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4583449/
https://www.ncbi.nlm.nih.gov/pubmed/26406890
http://dx.doi.org/10.1371/journal.pone.0139212
_version_ 1782391851210244096
author Gouveia-Figueira, Sandra
Karlsson, Jessica
Deplano, Alessandro
Hashemian, Sanaz
Svensson, Mona
Fredriksson Sundbom, Marcus
Congiu, Cenzo
Onnis, Valentina
Fowler, Christopher J.
author_facet Gouveia-Figueira, Sandra
Karlsson, Jessica
Deplano, Alessandro
Hashemian, Sanaz
Svensson, Mona
Fredriksson Sundbom, Marcus
Congiu, Cenzo
Onnis, Valentina
Fowler, Christopher J.
author_sort Gouveia-Figueira, Sandra
collection PubMed
description BACKGROUND: Increased endocannabinoid tonus by dual-action fatty acid amide hydrolase (FAAH) and substrate selective cyclooxygenase (COX-2) inhibitors is a promising approach for pain-relief. One such compound with this profile is 2-(2-fluorobiphenyl-4-yl)-N-(3-methylpyridin-2-yl)propanamide (Flu-AM1). These activities are shown by Flu-AM1 racemate, but it is not known whether its two single enantiomers behave differently, as is the case towards COX-2 for the parent flurbiprofen enantiomers. Further, the effects of the compound upon COX-2-derived lipids in intact cells are not known. METHODOLOGY/PRINCIPAL FINDINGS: COX inhibition was determined using an oxygraphic method with arachidonic acid and 2-arachidonoylglycerol (2-AG) as substrates. FAAH was assayed in mouse brain homogenates using anandamide (AEA) as substrate. Lipidomic analysis was conducted in unstimulated and lipopolysaccharide + interferon γ- stimulated RAW 264.7 macrophage cells. Both enantiomers inhibited COX-2 in a substrate-selective and time-dependent manner, with IC(50) values in the absence of a preincubation phase of: (R)-Flu-AM1, COX-1 (arachidonic acid) 6 μM; COX-2 (arachidonic acid) 20 μM; COX-2 (2-AG) 1 μM; (S)-Flu-AM1, COX-1 (arachidonic acid) 3 μM; COX-2 (arachidonic acid) 10 μM; COX-2 (2-AG) 0.7 μM. The compounds showed no enantiomeric selectivity in their FAAH inhibitory properties. (R)-Flu-AM1 (10 μM) greatly inhibited the production of prostaglandin D(2) and E(2) in both unstimulated and lipopolysaccharide + interferon γ- stimulated RAW 264.7 macrophage cells. Levels of 2-AG were not affected either by (R)-Flu-AM1 or by 10 μM flurbiprofen, either alone or in combination with the FAAH inhibitor URB597 (1 μM). CONCLUSIONS/SIGNIFICANCE: Both enantiomers of Flu-AM1 are more potent inhibitors of 2-AG compared to arachidonic acid oxygenation by COX-2. Inhibition of COX in lipopolysaccharide + interferon γ- stimulated RAW 264.7 cells is insufficient to affect 2-AG levels despite the large induction of COX-2 produced by this treatment.
format Online
Article
Text
id pubmed-4583449
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-45834492015-10-02 Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor Gouveia-Figueira, Sandra Karlsson, Jessica Deplano, Alessandro Hashemian, Sanaz Svensson, Mona Fredriksson Sundbom, Marcus Congiu, Cenzo Onnis, Valentina Fowler, Christopher J. PLoS One Research Article BACKGROUND: Increased endocannabinoid tonus by dual-action fatty acid amide hydrolase (FAAH) and substrate selective cyclooxygenase (COX-2) inhibitors is a promising approach for pain-relief. One such compound with this profile is 2-(2-fluorobiphenyl-4-yl)-N-(3-methylpyridin-2-yl)propanamide (Flu-AM1). These activities are shown by Flu-AM1 racemate, but it is not known whether its two single enantiomers behave differently, as is the case towards COX-2 for the parent flurbiprofen enantiomers. Further, the effects of the compound upon COX-2-derived lipids in intact cells are not known. METHODOLOGY/PRINCIPAL FINDINGS: COX inhibition was determined using an oxygraphic method with arachidonic acid and 2-arachidonoylglycerol (2-AG) as substrates. FAAH was assayed in mouse brain homogenates using anandamide (AEA) as substrate. Lipidomic analysis was conducted in unstimulated and lipopolysaccharide + interferon γ- stimulated RAW 264.7 macrophage cells. Both enantiomers inhibited COX-2 in a substrate-selective and time-dependent manner, with IC(50) values in the absence of a preincubation phase of: (R)-Flu-AM1, COX-1 (arachidonic acid) 6 μM; COX-2 (arachidonic acid) 20 μM; COX-2 (2-AG) 1 μM; (S)-Flu-AM1, COX-1 (arachidonic acid) 3 μM; COX-2 (arachidonic acid) 10 μM; COX-2 (2-AG) 0.7 μM. The compounds showed no enantiomeric selectivity in their FAAH inhibitory properties. (R)-Flu-AM1 (10 μM) greatly inhibited the production of prostaglandin D(2) and E(2) in both unstimulated and lipopolysaccharide + interferon γ- stimulated RAW 264.7 macrophage cells. Levels of 2-AG were not affected either by (R)-Flu-AM1 or by 10 μM flurbiprofen, either alone or in combination with the FAAH inhibitor URB597 (1 μM). CONCLUSIONS/SIGNIFICANCE: Both enantiomers of Flu-AM1 are more potent inhibitors of 2-AG compared to arachidonic acid oxygenation by COX-2. Inhibition of COX in lipopolysaccharide + interferon γ- stimulated RAW 264.7 cells is insufficient to affect 2-AG levels despite the large induction of COX-2 produced by this treatment. Public Library of Science 2015-09-25 /pmc/articles/PMC4583449/ /pubmed/26406890 http://dx.doi.org/10.1371/journal.pone.0139212 Text en © 2015 Gouveia-Figueira et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Gouveia-Figueira, Sandra
Karlsson, Jessica
Deplano, Alessandro
Hashemian, Sanaz
Svensson, Mona
Fredriksson Sundbom, Marcus
Congiu, Cenzo
Onnis, Valentina
Fowler, Christopher J.
Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor
title Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor
title_full Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor
title_fullStr Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor
title_full_unstemmed Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor
title_short Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor
title_sort characterisation of (r)-2-(2-fluorobiphenyl-4-yl)-n-(3-methylpyridin-2-yl)propanamide as a dual fatty acid amide hydrolase: cyclooxygenase inhibitor
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4583449/
https://www.ncbi.nlm.nih.gov/pubmed/26406890
http://dx.doi.org/10.1371/journal.pone.0139212
work_keys_str_mv AT gouveiafigueirasandra characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor
AT karlssonjessica characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor
AT deplanoalessandro characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor
AT hashemiansanaz characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor
AT svenssonmona characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor
AT fredrikssonsundbommarcus characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor
AT congiucenzo characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor
AT onnisvalentina characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor
AT fowlerchristopherj characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor